KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Other Non Operating Income (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Other Non Operating Income for 17 consecutive years, with $134.0 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 12.99% to $134.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $415.0 million through Dec 2025, up 142.69% year-over-year, with the annual reading at $548.0 million for FY2025, 45.74% up from the prior year.
  • Other Non Operating Income hit $134.0 million in Q4 2025 for Abbott Laboratories, up from $17.0 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $284.0 million in Q4 2021 to a low of -$24.0 million in Q4 2023.
  • Historically, Other Non Operating Income has averaged $65.8 million across 5 years, with a median of $74.0 million in 2021.
  • Biggest five-year swings in Other Non Operating Income: plummeted 400.0% in 2021 and later surged 2700.0% in 2022.
  • Year by year, Other Non Operating Income stood at $284.0 million in 2021, then plummeted by 95.07% to $14.0 million in 2022, then tumbled by 271.43% to -$24.0 million in 2023, then skyrocketed by 741.67% to $154.0 million in 2024, then fell by 12.99% to $134.0 million in 2025.
  • Business Quant data shows Other Non Operating Income for ABT at $134.0 million in Q4 2025, $17.0 million in Q3 2025, and $137.0 million in Q2 2025.